Instructions for use of Quizartinib

Quizatinib is an oral tyrosine kinase inhibitor mainly used to treat acute myeloid leukemia (AML) with FLT3-ITD mutations. AML is a malignant clonal disease derived from bone marrow hematopoietic stem cells, and FLT3-ITD mutation is an important molecular marker that is common in AML and associated with poor prognosis. Quizartinib can effectively block the abnormal signaling pathways caused by FLT3-ITD mutations by inhibiting the activity of FLT3 kinase, thereby inhibiting the proliferation of leukemia cells and inducing their apoptosis.

When using quizartinib, patients and their healthcare teams need to pay close attention to some key considerations to ensure the safety and effectiveness of the treatment. First, quizartinib may cause serious heart problems, especially if it is combined with certain other drugs. Therefore, patients should report all medications they are taking, including prescription drugs, over-the-counter drugs, and any supplements, to their doctor in detail before treatment to avoid potential drug interactions. If patients experience irregular heartbeat, dizziness, or a feeling of fainting, they should contact their doctor immediately.

Secondly, not all patients are suitable for Quizartinib. Avoid use in patients with known hypersensitivity to this drug or its components, or in patients with a history of severe cardiac arrhythmias, QT prolongation, long QT syndrome, ventricular arrhythmias, or torsade de pointes. In addition, patients with severely impaired liver function should also use this drug with caution, as the metabolism of the drug may be affected, thereby increasing the risk of adverse reactions.

During treatment, patients should receive regular health examinations and monitoring, especially electrocardiogram, liver and kidney function, and blood routine. Because quizartinib may prolong the QT interval, thereby increasing the risk of arrhythmias, regular electrocardiograms are particularly important. At the same time, patients may also experience adverse reactions such as nausea, vomiting, diarrhea, and fatigue. If severe discomfort or abnormal reactions occur, they must report to the doctor in time and consider adjusting the dosage or discontinuing the drug.

In short, as an effectiveFLT3-ITD mutated AML treatment drug, the use of quizartinib must strictly follow the doctor's recommendations and guidance. Close collaboration between patients and medical staff will help ensure the safety and effectiveness of the treatment process.

xa0

Reference materials:https://www.drugs.com/mtm/quizartinib.html